Related Experiment Video
Updated: Jan 10, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Aspirin monotherapy or DAPT after CABG in ACS? Insights from the TACSI Trial
1Department of Cardiac Surgery, Rabindranath Tagore International Institute of Cardiac Sciences, Narayana Health, 124, EM Bypass, Mukundapur, India.
Abstract:
Dual antiplatelet therapy (DAPT) is recommended after acute coronary syndrome (ACS), but evidence in coronary artery bypass graft (CABG) patients is limited. The TACSI (Dual Antiplatelet Therapy with Ticagrelor and Acetylsalicylic Acid [ASA] vs. ASA only after isolated Coronary Artery Bypass Grafting in patients with Acute Coronary Syndrome) Trial randomized 2201 ACS patients undergoing isolated CABG across 22 Nordic centres to Ticagrelor plus aspirin or Aspirin alone for 1 year. Ticagrelor plus aspirin did not reduce death, myocardial infarction, stroke, or repeat revascularization compared with aspirin alone at 1 year, but nearly doubled the risk of major bleeding. This challenges the assumption that DAPT, which is recommended in all cases after ACS, provides added benefit after CABG.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Angina IV: Management
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome V: Nursing Management

